Comirnaty (BNT162b2) is an mRNA vaccine developed by Pfizer and BioNTech that encodes the SARS-CoV-2 spike protein. It was the first COVID-19 vaccine to receive emergency use authorization and full FDA approval, achieving the fastest drug launch in history.
Comirnaty uses lipid nanoparticle-delivered mRNA encoding the SARS-CoV-2 spike protein. After injection, cells produce the spike protein, triggering both humoral (antibody) and cellular (T cell) immune responses against COVID-19.
Annual revenue trajectory
Revenue of competing drugs in the same class
4 indications
All approved therapeutic uses
Comirnaty was the dominant COVID-19 vaccine with >60% market share in developed markets. Revenue declining from $37.8B peak (2022) as pandemic transitions to endemic phase with annual booster campaigns.
Revenue expected to stabilize at $3-5B annually as annual COVID booster market matures. Pfizer/BioNTech exploring combination vaccines (COVID + flu) and expanding mRNA platform to other indications (RSV, shingles, flu).
| Drug | Company | Revenue |
|---|---|---|
| Spikevax (mRNA-1273) | Moderna | $6.7B |
| Novavax (NVX-CoV2373) | Novavax | $0.5B |
| Jcovden (Ad26.COV2.S) | J&J | $0.2B |
Revenue figures from company annual reports (FY2023). Clinical trial data from ClinicalTrials.gov. Competitive intelligence from Evaluate Pharma World Preview 2024 and IQVIA MIDAS. Market analysis by Medifirm Intelledge Global.